PeptiDream Inc. (4587.T) JPX
1,032.50
-15(-1.43%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
1,032.50
-15(-1.43%)
Currency In JPY
Sector
Healthcare
Industry
Biotechnology
Employees
621
First IPO Date
June 12, 2013
| Name | Title | Pay | Year Born |
| Patrick Crawford Reid | President, Chief Executive Officer & Representative Director | 126.8M | 1975 |
| Yen Ting Chen | Head of Business Development & Alliance Management | 0 | N/A |
| Christian Cunningham | Chief Scientific Officer | 0 | N/A |
| Masato Murakami | Executive VP of Radiopharmaceuticals Business, Chief Medical Officer & Director | 0 | 1974 |
| Yuko Okimoto | IR & Public Relations Director | 0 | N/A |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.